PerPrev-CID Establishes Patient Advisory Panel – Shaping Research with and for Patients

In September 2025, the PerPrev-CID consortium launched its Patient Advisory Panel (PAP) – an important step in ensuring that patients are actively involved in shaping the project’s direction. The panel brings together patient research partners (PRPs) from the European Alliance of Associations for Rheumatology (EULAR) and the International Federation of Crohn’s & Ulcerative Colitis Associations (IFCCA), two leading umbrella organisations representing patient communities across Europe and internationally.

From now on, patients are actively contributing to the project’s development by sharing their lived experiences, helping to shape decisions, and ensuring that research remains closely connected to the needs and realities of people living with chronic inflammatory diseases. During the kick-off meeting, the consortium and the newly formed panel explored the science behind PerPrev-CID and discussed how patient voices will guide each step of the journey. This collaboration goes beyond consultation: patient representatives will contribute to study design, review project materials, and help shape communication and dissemination activities. Their ongoing input ensures that project outcomes are meaningful, accessible, and truly relevant for those affected by rheumatoid arthritis (RA) and inflammatory bowel disease (IBD).

The establishment of the PAP marks the beginning of a close and continuous partnership where patient insight and scientific expertise work hand in hand to advance research and improve quality of life of people living with chronic disease. Through this commitment, PerPrev-CID reinforces its mission to co-create research that makes a real difference.